Prim (XMAD:PRM) Net Loan


XMAD:PRM Prim SA XMAD:PRM
77 GF Score
Price €13.40
GF Value €7.71
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prim Net Loan?

Net Loan only applies to banks and insurance companies.

XMAD:PRM
77GF Score
Prim SA XMAD:PRM
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prim (XMAD:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Prim stock appears to be overvalued. The current stock price of €13.40 is trading 73.8% above its estimated GF Value™ of €7.71. GuruFocus considers Prim to be Significantly Overvalued.

Key valuation signals for XMAD:PRM:

  • Net Loan:
  • GF Value™: €7.71 vs. price of €13.40 (73.8% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prim Business Description

Other Exchanges 0FP0:UK5P1:Germany
Address Calle F, numero 15, Poligono Industrial 1, Mostoles, Madrid, ESP, 28938
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
77GF Score

Get the complete analysis for XMAD:PRM

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.40
Price
€7.71
GF Value